Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + mFOLFIRINOX
- Development stage
- Unknown
- Lead developer
- Zhejiang University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of the anti-PD-1 monoclonal antibody sintilimab and the modified FOLFIRINOX (mFOLFIRINOX) chemotherapy regimen. Sintilimab is a biologic immunotherapy that targets the PD-1 receptor to enhance the immune system's ability to detect and destroy cancer cells. The mFOLFIRINOX component is a multi-agent chemotherapy regimen comprising fluorouracil, leucovorin, irinotecan, and oxaliplatin. This combination is being investigated by researchers at Zhejiang University as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), aiming to leverage the synergistic effects of immune checkpoint inhibition and cytotoxic chemotherapy to improve clinical outcomes in this aggressive malignancy.
- Other names
- sintilimab + modified FOLFIRINOXAnti-PD-1 Antibody plus mFOLFIRINOXAnti-PD1 Antibody plus mFOLFIRINOXAnti-PD 1 Antibody plus mFOLFIRINOX
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on sintilimab + mFOLFIRINOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + mFOLFIRINOX.